IMMUNEPOTENT CRP (bovine dialyzable leukocyte extract) adjuvant immunotherapy: a phase I study in non-small cell lung cancer patients

References

• Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer. In: DeVita VT, Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 5th edition. Philadelphia: Lippincott-Raven, 1997:858–911.
   Google Scholar
• INEGI. Estadísticas Demográficas 2005. INEGI, Distrito FederalMex. 2006.
   Google Scholar
• Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 2000 2000; 50: 7–33
   PubMed Web of Science ®Google Scholar
• Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33–64
   PubMed Web of Science ®Google Scholar
• Sethi T. Lung cancer. Thorax 2002; 57: 992–3
   PubMedGoogle Scholar
• Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710–7
   PubMed Web of Science ®Google Scholar
• Van Houtte P. The role of radiotherapy and the value of combined treatment in lung cancer. Eur J Cancer 2001; 37(Suppl 7)S91–8
   Google Scholar
• Patel RR, Mehta M. Three-dimensional conformal radiotherapy for lung cancer: promises and pitfalls. Curr Oncol Rep 2002; 4: 347–53
   PubMedGoogle Scholar
• Sim S, Rosenzweig KE, Schindelheim R, et al. Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001; 51: 660–5
   PubMed Web of Science ®Google Scholar
• Socinski MA, Rosenman JG, Halle J , et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 2001;92:1213–23.
   PubMed Web of Science ®Google Scholar
• Willner J, Schmidt M, Kirschner J, et al. Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol) and 3D-conformal radiotherapy of stage III inoperable non-small cell lung cancer. Results of a dose escalation study. Lung Cancer 2001; 32: 163–71
   PubMed Web of Science ®Google Scholar
• Curran WJ, Jr, Scott C, Langer C, et al. Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small-cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410 (abstract). Proc Am Soc Clin Oncol 2000; 19: 484a
   Google Scholar
• Kraut JM, Rusch VW, Crowley JJ, et al. Induction of chemoradiation plus surgical resection is a feasible and highly effective treatment for Pancoast tumors: initial results of SWOG 9416 (Intergroup 0166) trial (abstract). Proc Am Soc Clin Oncol 2000; 19: 487a
   Google Scholar
• Swisher SG, Roth JA, Carbone DP. Genetic and immunologic therapies for lung cancer. Semin Oncol 2002; 29(Suppl 4)95–101
   PubMedGoogle Scholar
• Sakamoto J, Teramukai S, Watanabe Y, et al. Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer. J Immunother 2001; 24: 250–6
   Web of Science ®Google Scholar
• Kirkpatrick CH. Structural nature and functions of transfer factors. Ann NY Acad Sci 1993; 685: 362–8
   PubMed Web of Science ®Google Scholar
• Franco-Molina MA, Mendoza-Gamboa E, Castillo-Leon L, et al. Bovine dialyzable leukocyte extract protects against LPS-induced, murine endotoxic shock. Int Immunopharmacol 2004; 15: 1577–86
   Google Scholar
• Franco-Molina MA, Mendoza-Gamboa E, Castillo-Leon L, et al. Bovine dialyzable leukocyte extract modulates the nitric oxide and pro-inflammatory cytokine production in lipopolysaccharide-stimulated murine peritoneal macrophages in vitro. Med Food 2005; 8: 20–6
   PubMed Web of Science ®Google Scholar
• Franco-Molina MA, Mendoza-Gamboa E, Castillo-Tello P, et al. In vitro antibacterial activity of bovine dialyzable leukocyte extract. Immunopharmacol Immunotoxicol 2006; 28: 471–83
   PubMed Web of Science ®Google Scholar
• Franco-Molina MA, Mendoza-Gamboa E, Miranda-Hernandez D, et al. In vitro effects of bovine dialyzable leukocyte extract (bDLE) in cancer cells. Cytotherapy 2006; 8: 408–14
   PubMed Web of Science ®Google Scholar
• Vacek A, Hofer M, Barnet K, et al. Positive effects of dialyzable leukocyte extract (DLE) on recovery of mouse haemopoiesis suppressed by ionizing radiation and on proliferation of haemopoietic progenitor cells in vitro. Int J Immunopharmacol 2000; 22: 623–34
   PubMed Web of Science ®Google Scholar
• Alvarez-Thull L, Kirkpatrick CH. Profiles of cytokine production in recipients of transfer factors. Biotherapy 1996; 9: 55–9
   PubMedGoogle Scholar
• McMeeking A, Borkowsky W, Klesius PH, et al. A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS. J Infect Dis 1990; 161: 108–12
   PubMed Web of Science ®Google Scholar
• Chase MW. The cellular transfer of cutaneous hypersensitivity to tuberculin. Proc Soc Exp Biol Med 1945; 59: 134–6
   Web of Science ®Google Scholar
• Kirkpatrick CH, Rozzo SJ, Mascali JJ, Merryman CF. Murine transfer factor. II. Transfer of delayed hypersensitivity to synthetic antigens. J Immunol 1985; 134: 1723–7
   PubMed Web of Science ®Google Scholar
• Kirkpatrick CH, Rozzo SJ, Mascali JJ. Murine transfer factor. III. Specific interactions between transfer factor and antigen. J Immunol 1985; 135: 4027–33
   PubMed Web of Science ®Google Scholar
• Bloom BR. Does transfer factor act specifically or as an immunologic adjuvant?. N Engl J Med 1980; 288: 908–9
   Google Scholar
• Levin AS, Spitler LE, Stites DP, Fudenberg HH. Wiskott–Aldrich syndrome, a genetically determined cellular immunologic deficiency: clinical and laboratory responses to therapy with transfer factor. Proc Natl Acad Sci USA 1970; 67: 821–8
   PubMed Web of Science ®Google Scholar
• Whyte RI, Schork MA, Sloan H, et al. Adjuvant treatment using transfer factor for bronchogenic carcinoma: long-term follow-up. Ann Thorac Surg 1992; 53: 391–6
   PubMed Web of Science ®Google Scholar
• Dorothee G, Vergnon I, Menez J, et al. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity. J Immunol 2002; 2: 809–17
   Google Scholar
• Karnofsky DA, Abelmann WH, Craver LF, et al. The use of the nitrogen mustards in palliative treatment of carcinoma. Cancer 1948; 1: 634–56
   Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
   PubMed Web of Science ®Google Scholar
• Rodriguez-Balderrama I, Pérez-Martinez PY, Jimenez-González GA , et al. Uso del factor de transferencia en recién nacidos con choque séptico. Med Univ 2000;7:125–30.
   Google Scholar